What is Cagrilintide?
Cagrilintide is a long-acting amylin analogue investigated for weight management. Studies of cagrilintide alone and studies combining it with semaglutide address different interventions.
Mechanism & research focus
Its pharmacology builds on amylin-related signaling involved in satiety and energy intake. It is distinct from a GLP-1 receptor agonist, even when the two classes are studied together.
What the research covers
A 2021 randomized phase 2 study with 706 participants reported greater weight reduction with cagrilintide than placebo. The 2025 REDEFINE-1 phase 3 study included cagrilintide-only, semaglutide-only, combination and placebo arms; its main reported comparison concerned the combination.
What remains uncertain
Combination results must not be presented as cagrilintide-alone results. Gastrointestinal adverse events occurred in clinical studies. These findings concern defined trial preparations and do not verify the identity, activity or interchangeability of a research vial.
The evidence label describes the linked research, not the suitability of a catalog product for use in people. Formulation, identity, purity, and measured content must be assessed separately.
Sources & studies
Once-weekly cagrilintide for weight management: randomized phase 2 trial ↗
Monotherapy evidence, with placebo and active comparator groups and adverse-event reporting.
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity ↗
REDEFINE-1 includes component arms; combination outcomes cannot be attributed to cagrilintide alone.
Read the full paper for its design, controls and limitations. A source link is not a claim that its tested material matches a DA formulation.
Catalog formats & documentation
Formats grouped by compound identity. Availability and batch documentation remain on Disguised Alpha.
Original DA reference: Cagrilintide research guide ↗